Population modelling of nilotinib exposure <i>vs</i> . longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model
The ability to distinguish molecular response between lines of therapy is demonstrated using model-based analysis. These nilotinib information enable the extrapolation of novel tyrosine kinase inhibitors (e.g., asciminib) response to other lines of therapy in patients with CML-CP.
Authors
- Sherwin K. B. Sy (ORCID: https://orcid.org/0000-0001-6405-9130)
- Christelle Darstein
- S. S. Kapoor (ORCID: https://orcid.org/0000-0003-4216-8488)
- Kohinoor Dasgupta
- Deok Yong Yoon (ORCID: https://orcid.org/0000-0002-5281-8811)
- Matthias Hoch (ORCID: https://orcid.org/0009-0005-1033-2716)
- Kai Grosch
- Yiqun Yang
Institutions
- Novartis (Switzerland) (CH)
- Novartis (India) (IN)
- Novartis (United States) (US)
- Tris Pharma (United States) (US)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1111/bcp.16381
- Citations
- 2
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Novartis Pharmaceuticals Corporation